Grail Inc. (NASDAQ:GRAL) is a top emerging technology stock to invest in, with Morgan Stanley giving it an Equal Weight rating and a price target of $110. In Q3 2025, Grail reported a 26% revenue increase driven by the Galleri multi-cancer detection test. Positive clinical milestones showed improved cancer detection rates and a new partnership with Samsung for commercialization in Asia.

Grail Inc. (NASDAQ:GRAL) is a healthcare company offering multi-cancer early detection testing. While it shows investment potential, other AI stocks may offer greater upside with less risk. Grail’s recent growth and partnerships indicate a promising future in the healthcare sector.

Read more at Yahoo Finance: Morgan Stanley Eyes Emerging Growth for Grail (GRAL) as Sector Valuations Reach Equilibrium